Hennion & Walsh Asset Management Inc. Acquires 20,837 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Hennion & Walsh Asset Management Inc. grew its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 7.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 310,116 shares of the company’s stock after purchasing an additional 20,837 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $5,588,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of TEVA. Janney Montgomery Scott LLC raised its stake in shares of Teva Pharmaceutical Industries by 13.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 1,372,477 shares of the company’s stock worth $19,366,000 after acquiring an additional 164,614 shares in the last quarter. QRG Capital Management Inc. raised its stake in shares of Teva Pharmaceutical Industries by 53.7% during the 1st quarter. QRG Capital Management Inc. now owns 143,747 shares of the company’s stock worth $2,028,000 after acquiring an additional 50,247 shares in the last quarter. Capital Wealth Planning LLC bought a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth approximately $2,169,000. SG Americas Securities LLC raised its stake in shares of Teva Pharmaceutical Industries by 12.0% during the 1st quarter. SG Americas Securities LLC now owns 610,407 shares of the company’s stock worth $8,613,000 after acquiring an additional 65,529 shares in the last quarter. Finally, Coronation Fund Managers Ltd. bought a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $1,334,000. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA opened at $18.41 on Thursday. The company’s fifty day moving average price is $18.02 and its 200 day moving average price is $16.72. Teva Pharmaceutical Industries Limited has a 1 year low of $8.07 and a 1 year high of $19.08. The company has a market capitalization of $20.85 billion, a PE ratio of -47.19, a price-to-earnings-growth ratio of 1.32 and a beta of 0.88. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. The firm had revenue of $4.16 billion for the quarter, compared to the consensus estimate of $3.99 billion. On average, research analysts predict that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current year.

Wall Street Analyst Weigh In

TEVA has been the topic of several research analyst reports. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday. UBS Group boosted their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. JPMorgan Chase & Co. boosted their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday. Finally, Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Wednesday, July 10th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average price target of $19.67.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 24,537 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the transaction, the insider now directly owns 45,060 shares in the company, valued at approximately $777,285. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.55% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.